Global lung cancer screening software market is anticipated to grow at a significant CAGR of 19.5% during the forecast period (2024-2031).Computer-Aided Detection (CAD) systems help radiologists analyze medical images to identify lung nodules or lesions. Artificial Intelligence (AI) and machine learning technologies enhance lung cancer screening by analyzing large volumes of data. Image segmentation and analysis help radiologists assess lung morphology and disease progression more accurately. Quantitative imaging biomarkers help differentiate between benign and malignant nodules and monitor changes over time. Structured reporting tools improve communication and data sharing among healthcare providers. Clinical Decision Support Systems (CDSS) offer evidence-based recommendations and decision-support tools for lung cancer screening. Integration with Electronic Health Records (EHR) enhances care coordination and longitudinal tracking of lung cancer screening outcomes.Furthermore, the market has seen significant growth primarily owing to increased focus on R&D by both public and private organizations and growing applications. For instance, In January 2024, Nova Scotia introduced a screening program for individuals aged 50-74 with 20+ years of daily smoking, involving clinical assessments and chest CT scans, to assess their lung cancer risk.
Browse the full report description of “Lung Cancer Screening Software Market Size, Share & Trends Analysis Report by Cancer Type (Non-small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer) by Diagnosis Type (Dose Spiral, CT Scan, and Chest X-ray) and by End-User (Hospitals & Clinics, and Diagnostic Centres) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/lung-cancer-screening-software-market
In October 2023,DELFI Diagnostics launched FirstLook Lung, a low-dose CT scan-based blood test for lung cancer detection, offering a 99.7% negative predictive value and a 99.7% positive predictive value, based on fragmentomics.
In May 2022, BC Cancer launched a lung cancer screening program, providing access to eligible high-risk individuals at 36 sites across the province. The program is best suited for those aged 55-74, currently or previously smoking, and with a 20-year smoking history. The program offers equitable access, early detection, improved survival rates, and consistent, high-level screening and prevention.
In June 2020,Roche launched its uPath PD-L1 digital pathology platform for non-small cell lung cancer, utilizing AI to provide pathologists with reproducible assessments, aiding diagnosis and treatment options, and highlighting positive and negative tumor cells.
The market number available for – 2023-2031
• Base year- 2023
• Forecast period- 2024-2031
• Segment Covered-
o By Cancer Type
o By Diagnosis Type
o By End User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- FUJIFILM Holdings Corp., McKesson Corp., Siemens Healthineers Co., Nuance Communications, Inc., VIDA Diagnostics Inc. among others.
Key questions addressed by the report.
Global Lung Cancer Screening Software Market Report Segment
By Cancer Type
By Diagnosis Type
By End-User
Global Lung Cancer Screening Software Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lung-cancer-screening-software-market